Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tyrx, a developer of convergent drug-device products, has appointed David Elliot, Jr, as its new COO, responsible for commercial operations.
Subscribe to our email newsletter
Mr Elliot joins Tyrx from Valam, a provider of laser-based antimicrobial and vascular plaque destruction therapies, where he was president and CEO and remains a board director. Prior to Valam, Mr Elliot was president, COO and board director of VistaCare.
Mr Elliot has earned a bachelor of arts in English from Connecticut College and an MBA from the University of Chicago.
Bill Edelman, president and CEO of Tyrx, said: “David’s experience in the cardiac rhythm management space, as well as his demonstrated track record of achievement in entrepreneurial settings, provides a powerful combination of skills to support the commercialization of our AIGISRx platform and to advance our forward looking strategies to bring Tyrx’s unique device/drug products to the market.”